Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $25.4 million.

  • Cidara Therapeutics' Shares Outstanding (Weighted Average) rose 260.29% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 260.29%. This contributed to the annual value of $7.0 million for FY2024, which is 55.84% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Shares Outstanding (Weighted Average) stood at $25.4 million, which was up 95.52% from $13.0 million recorded in Q2 2025.
  • Cidara Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $25.4 million for Q3 2025, and its period low was $2.4 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $8.2 million, with a median of $4.6 million in 2024.
  • Data for Cidara Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 260.29% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Shares Outstanding (Weighted Average) stood at $3.3 million in 2021, then grew by 7.40% to $3.6 million in 2022, then increased by 26.27% to $4.5 million in 2023, then soared by 55.84% to $7.0 million in 2024, then skyrocketed by 260.29% to $25.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $25.4 million for Q3 2025, versus $13.0 million for Q2 2025 and $11.0 million for Q1 2025.